Merrill Lynch maintains Actelion at sell

Actelion was maintained by Merrill Lynch analyst Erica Whittaker at a sell rating after Tracleer failed to meet endpoints in phase 2 and phase 3 trials for lung fibrosis. The results were expected, Merrill Lynch said. There is emerging competition for Tracleer from Pfizer and others. The next product news won't be until mid-2006 for phase 2 and phase 3 data on clazosentan in the prevention of vasospasms following subarachnoid hemorrhage. Shares of the Basel, Switzerland, biotechnology company were unchanged at CHF 108.50.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.